MDB Capital Holdings (MDBH) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for December 2, 2025, to be held virtually; shareholders must register in advance to attend and vote.
Shareholders will vote on electing seven directors and ratifying the appointment of RBSM LLP as the independent auditor for fiscal year 2025.
Only holders of Class A and Class B shares as of October 14, 2025, are eligible to vote; Class B shares carry five votes per share, Class A one vote per share.
Board recommends voting FOR all director nominees and FOR auditor ratification.
Voting matters and shareholder proposals
Proposals include election of seven directors and ratification of RBSM LLP as auditor.
Shareholders may submit other business, but none is anticipated.
Shareholder proposals for the 2026 meeting must be received by February 1, 2026, for proxy inclusion; advance notice required for other proposals.
Universal proxy rules apply for director nominations; notice required by February 1, 2026.
Board of directors and corporate governance
Board consists of seven members; three are independent per Nasdaq standards.
CEO Christopher Marlett serves as Chairman; Daniel Torpey is Lead Independent Director.
Company is a controlled company under Nasdaq rules due to Class B share structure, exempt from certain governance requirements.
Audit committee is comprised solely of independent directors; no compensation or nominations committee due to controlled status.
Code of business conduct and insider trading policy in place; clawback policy adopted for excess compensation.
Latest events from MDB Capital Holdings
- Public venture model delivers liquid, tax-advantaged access to high-growth companies.MDBH
Investor presentation16 Mar 2026 - IPO launches with LTIR, offering downside protection and incentives for long-term investors.MDBH
Status Update15 Jan 2026 - Invizyne IPO, deep tech pipeline, and investor growth drive expansion despite higher losses.MDBH
Q3 202412 Jan 2026 - eXoZymes IPO and deconsolidation clarify results as platform and investor base expand.MDBH
Q4 202426 Dec 2025 - Shareholders will vote on directors, executive pay, auditor ratification, and governance policies.MDBH
Proxy Filing2 Dec 2025 - Q2 2025 net loss rose to $8.25M as focus shifts to profitable IPOs and a PatentVest spin-off.MDBH
Q2 202523 Nov 2025 - Scaling launches and major equity deals position for upside as market recovery is expected.MDBH
Q3 202521 Nov 2025 - Q1 2025 saw strong financings, platform growth, and a volatile portfolio amid macro risks.MDBH
Q1 202512 Nov 2025 - Scaling curated public ventures, prioritizing leadership and innovation in small-cap IPOs.MDBH
LD Micro Main Event XIX Investor Conference21 Oct 2025